Latest Development Pipeline News

Mustera Property Group reported a 45% revenue increase to $7.28 million for the half-year ending December 2025, driven by strong sales at its Forbes Residences project. Despite this growth, the company posted a net loss of $724,430, narrowing its deficit from the previous year as it advances its key North Fremantle development.

Dexus has announced a 19.3 cents per security distribution for HY26, aligned with its updated payout policy, alongside robust financial results and a strategic 10% on-market buyback to address valuation gaps.

Polymetals Resources has reported its maiden revenue from the Endeavor Mine with first concentrate shipments, yet posted a substantial half-year loss of $34.5 million. Operational setbacks and exploration advances mark a pivotal phase for the company.

Desane Group Holdings reports a modest half-year profit with stable assets and gearing, completes a key property sale, and pushes forward with a major industrial development in Penrith.

Carnegie Clean Energy reported a $1.7 million loss for the half-year ending December 2025, while pushing forward with key wave energy projects and securing $2.1 million in fresh capital.

Ingenia Communities reports a steady first half of FY26, maintaining full-year guidance at the top of its range, driven by accelerating development settlements and growth across rental and holiday segments.

Neurotech International has reported positive long-term safety results for its lead drug candidate NTI164, bolstering its path towards regulatory approval and chronic use in paediatric neurological disorders.

Horizon Gold has reported significant high-grade gold intercepts from recent drilling at its Kingfisher prospect within the Gum Creek Gold Project, revealing new down-plunge extensions and enhancing the project's resource outlook.

Mesoblast Limited is set to release its half-year financial results and operational update, spotlighting its FDA-approved cell therapy and expanding international partnerships.

Cambium Bio has secured FDA clearance to begin Phase 3 dosing for its lead ophthalmology product, Elate Ocular®, alongside key global partnerships and a $2.4 million capital injection from a major shareholder.

Newmont Corporation’s 2025 Annual Report reveals a robust financial performance driven by higher gold prices and portfolio optimisation, alongside significant progress in key development projects and sustainability initiatives.

Peet Limited has reported a robust half-year performance with statutory profit doubling and a significant dividend increase, underpinned by strong sales and settlements across key Australian markets.